Trial Profile
Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Erectile dysfunction; Restenosis
- Focus First in man; Proof of concept; Therapeutic Use
- Acronyms PERFECT-ABSORB
- 01 Sep 2020 Status changed to completed.
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology.
- 15 Jul 2015 New trial record